📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

C286, an orally available retinoic acid receptor ß agonist drug, regulates multiple pathways to achieve spinal cord injury repair (2024)

First Author: Goncalves M

Attributed to: A phase 1 trial of a retinoic acid receptor beta agonist for the treatment of spinal cord injury funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.3389/fnmol.2024.1411384

Publication URI: http://dx.doi.org/10.3389/fnmol.2024.1411384

Type: Journal Article/Review

Parent Publication: Frontiers in Molecular Neuroscience